Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9378MR)

This product GTTS-WQ9378MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9378MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15795MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ6611MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2031MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ2061MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ13423MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ6839MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ15233MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ14759MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-35
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW